Negative / Null Result ReportOpen accessMedicine

HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in mice.

Thaiz Ferraz Borin; Debora A P C Zuccari; Bruna V Jardim-Perassi; Lívia C Ferreira; A S M Iskander; Nadimpalli Ravi S Varma; Adarsh Shankar; Austin M Guo · 2014 · PLoS ONE

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

A selective inhibitor of 20-HETE synthesis, HET0016, has been reported to inhibit angiogenesis. 20-HETE has been known as a second mitogenic messenger of angiogenesis inducing growth factors. HET0016 effects were analyzed on MDA-MB-231 derived breast cancer in mouse and in vitro cell line. MDA-MB-231 tumor cells were implanted in animals' right flank and randomly assigned to early (1 and 2), starting treatments on day 0, or delayed groups (3 and 4) on day 8 after implantation of tumor. Animals received HET0016 (10 mg/kg) treatment via intraperitoneal injection for 5 days/week for either 3 or 4

Abstract by Thaiz Ferraz Borin; Debora A P C Zuccari; Bruna V Jardim-Perassi; Lívia C Ferreira; A S M Iskander; Nadimpalli Ravi S Varma; Adarsh Shankar; Austin M Guo, PLoS ONE (2014) — licensed CC BY 4.0.

Read the full paper (open access)